Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management

por Enebo, Lone B, Berthelsen, Kasper K, Kankam, Martin, Lund, Michael T, Rubino, Domenica M, Satylganova, Altynai, Lau, David C W
Publicado 2021

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

por Kosiborod, Mikhail N., Bhatta, Meena, Davies, Melanie, Deanfield, John E., Garvey, W. Timothy, Khalid, Usman, Kushner, Robert, Rubino, Domenica M., Zeuthen, Niels, Verma, Subodh
Publicado 2022

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss...

por Wharton, Sean, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Goldman, Bryan, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M., Thomsen, Mette, Wadden, Thomas A., Pedersen, Sue D.
Publicado 2021

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, pla...

por Verma, Subodh, Bhatta, Meena, Davies, Melanie, Deanfield, John E., Garvey, W. Timothy, Jensen, Camilla, Kandler, Kristian, Kushner, Robert F., Rubino, Domenica M., Kosiborod, Mikhail N.
Publicado 2022

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

por Rubino, Domenica M, Abrahamsson, Niclas, Davies, Melanie, Hesse, Dan, Greenway, Frank L, Jensen, Camilla, Lingvay, Ildiko, Mosenzon, Ofri, Rosenstock, Julio, Rubio, Miguel A, Rudofsky, Gottfried, Tadayon, Sayeh, Wadden, Thomas A, Dicker, Dror
Publicado 2021